Organon & Co. (OGN) Competitors $11.06 -0.24 (-2.08%) Closing price 03:59 PM EasternExtended Trading$11.06 0.00 (0.00%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock OGN vs. SMMT, GMAB, RDY, MRNA, VTRS, QGEN, ASND, ROIV, LNTH, and TGTXShould you be buying Organon & Co. stock or one of its competitors? The main competitors of Organon & Co. include Summit Therapeutics (SMMT), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Moderna (MRNA), Viatris (VTRS), Qiagen (QGEN), Ascendis Pharma A/S (ASND), Roivant Sciences (ROIV), Lantheus (LNTH), and TG Therapeutics (TGTX). These companies are all part of the "pharmaceutical products" industry. Organon & Co. vs. Summit Therapeutics Genmab A/S Dr. Reddy's Laboratories Moderna Viatris Qiagen Ascendis Pharma A/S Roivant Sciences Lantheus TG Therapeutics Summit Therapeutics (NASDAQ:SMMT) and Organon & Co. (NYSE:OGN) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment, community ranking and analyst recommendations. Do insiders and institutionals hold more shares of SMMT or OGN? 4.6% of Summit Therapeutics shares are held by institutional investors. Comparatively, 77.4% of Organon & Co. shares are held by institutional investors. 88.3% of Summit Therapeutics shares are held by company insiders. Comparatively, 1.4% of Organon & Co. shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the MarketBeat Community believe in SMMT or OGN? Summit Therapeutics received 290 more outperform votes than Organon & Co. when rated by MarketBeat users. Likewise, 58.44% of users gave Summit Therapeutics an outperform vote while only 33.33% of users gave Organon & Co. an outperform vote. CompanyUnderperformOutperformSummit TherapeuticsOutperform Votes30858.44% Underperform Votes21941.56% Organon & Co.Outperform Votes1833.33% Underperform Votes3666.67% Does the media prefer SMMT or OGN? In the previous week, Organon & Co. had 6 more articles in the media than Summit Therapeutics. MarketBeat recorded 19 mentions for Organon & Co. and 13 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 0.98 beat Organon & Co.'s score of 0.73 indicating that Summit Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Organon & Co. 7 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate SMMT or OGN? Summit Therapeutics presently has a consensus price target of $35.40, indicating a potential upside of 35.48%. Organon & Co. has a consensus price target of $20.60, indicating a potential upside of 82.46%. Given Organon & Co.'s higher possible upside, analysts clearly believe Organon & Co. is more favorable than Summit Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Summit Therapeutics 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 3.00Organon & Co. 1 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.43 Is SMMT or OGN more profitable? Organon & Co. has a net margin of 13.49% compared to Summit Therapeutics' net margin of 0.00%. Organon & Co.'s return on equity of 431.62% beat Summit Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Summit TherapeuticsN/A -85.42% -52.66% Organon & Co. 13.49%431.62%8.03% Which has better valuation and earnings, SMMT or OGN? Organon & Co. has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSummit Therapeutics$700K27,536.54-$614.93M-$0.31-84.29Organon & Co.$6.40B0.45$864M$3.333.39 Which has more risk & volatility, SMMT or OGN? Summit Therapeutics has a beta of -0.46, suggesting that its share price is 146% less volatile than the S&P 500. Comparatively, Organon & Co. has a beta of 0.73, suggesting that its share price is 27% less volatile than the S&P 500. SummaryOrganon & Co. beats Summit Therapeutics on 12 of the 19 factors compared between the two stocks. Remove Ads Get Organon & Co. News Delivered to You Automatically Sign up to receive the latest news and ratings for OGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OGN vs. The Competition Export to ExcelMetricOrganon & Co.Pharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$2.88B$6.35B$5.35B$18.51BDividend Yield9.80%3.23%5.11%4.24%P/E Ratio3.396.7721.7631.06Price / Sales0.45229.14376.0326.47Price / Cash3.1265.6738.1517.54Price / Book-41.815.886.444.29Net Income$864M$141.32M$3.20B$1.02B7 Day Performance-2.55%8.32%6.16%6.63%1 Month Performance-26.38%-12.93%-8.82%-6.86%1 Year Performance-36.25%-12.47%9.66%1.19% Organon & Co. Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OGNOrganon & Co.4.7988 of 5 stars$11.07-2.1%$20.60+86.2%-35.3%$2.85B$6.40B3.3210,000Short Interest ↓SMMTSummit Therapeutics2.6205 of 5 stars$17.32-0.2%$35.40+104.4%+613.0%$12.78B$700,000.00-61.85110News CoverageGMABGenmab A/S4.2162 of 5 stars$18.19-1.1%$41.33+127.2%-34.0%$12.04B$21.53B10.451,660Short Interest ↓Gap DownHigh Trading VolumeRDYDr. Reddy's Laboratories3.3658 of 5 stars$12.59+1.8%$17.00+35.1%-7.2%$10.51B$311.31B20.0424,800Positive NewsHigh Trading VolumeMRNAModerna4.3298 of 5 stars$25.64+2.1%$59.00+130.1%-74.5%$9.91B$3.20B-2.763,900Positive NewsVTRSViatris2.963 of 5 stars$7.61-0.1%$10.50+38.0%-32.7%$9.08B$14.74B-10.2837,000News CoverageHigh Trading VolumeQGENQiagen3.4768 of 5 stars$40.33+5.4%$47.71+18.3%+8.3%$8.96B$1.98B112.296,030High Trading VolumeASNDAscendis Pharma A/S2.3124 of 5 stars$140.14-1.8%$204.64+46.0%+6.5%$8.50B$363.64M-19.741,017News CoveragePositive NewsROIVRoivant Sciences2.6217 of 5 stars$9.26-2.1%$17.50+89.0%-6.9%$6.61B$122.59M-61.73860Positive NewsHigh Trading VolumeLNTHLantheus4.3397 of 5 stars$95.45+5.0%$129.43+35.6%+68.0%$6.54B$1.53B15.88700Positive NewsTGTXTG Therapeutics3.3135 of 5 stars$37.25-0.3%$40.67+9.2%+171.3%$5.85B$329.00M-372.46290Positive News Remove Ads Related Companies and Tools Related Companies SMMT Alternatives GMAB Alternatives RDY Alternatives MRNA Alternatives VTRS Alternatives QGEN Alternatives ASND Alternatives ROIV Alternatives LNTH Alternatives TGTX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:OGN) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Organon & Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Organon & Co. With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
